AbbVie Inc. Stock price

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 04:00:02 2024-02-09 pm EST 5-day change 1st Jan Change
174.1 USD -0.41% Intraday chart for AbbVie Inc. +3.21% +12.33%
Sales 2023 54.32B Sales 2024 * 54.42B Capitalization 307B
Net income 2023 4.86B Net income 2024 * 9.57B EV / Sales 2023 5.04 x
Net Debt 2023 * 45.68B Net Debt 2024 * 46.42B EV / Sales 2024 * 6.5 x
P/E ratio 2023
57 x
P/E ratio 2024 *
31.3 x
Employees 50,000
Yield 2023 *
3.42%
Yield 2024 *
3.56%
Free-Float 96.74%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.41%
1 week+3.21%
Current month+5.89%
1 month+5.57%
3 months+25.61%
6 months+14.95%
Current year+12.33%
More quotes
1 week
168.45
Extreme 168.45
175.91
1 month
161.00
Extreme 161
175.91
Current year
154.77
Extreme 154.7704
175.91
1 year
130.96
Extreme 130.9601
175.91
3 years
102.05
Extreme 102.05
175.91
5 years
62.55
Extreme 62.55
175.91
10 years
45.45
Extreme 45.45
175.91
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 12-12-31
Director of Finance/CFO 57 12-12-31
President 53 11-12-31
Members of the board TitleAgeSince
Director/Board Member 63 12-12-31
Director/Board Member 66 12-12-31
Director/Board Member 70 12-12-31
More insiders
Date Price Change Volume
24-02-09 174.1 -0.41% 3,502,661
24-02-08 174.8 -0.13% 5,709,326
24-02-07 175 +0.99% 6,409,084
24-02-06 173.3 +1.19% 7,038,000
24-02-05 171.3 +1.54% 6,486,886

Delayed Quote Nyse, February 09, 2024 at 04:00 pm EST

More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (78.7%), Germany (2.3%), Canada (2%), Japan (1.6%), China (1.6%), France (1.4%), Australia (0.9%), Spain (0.9%), the United Kingdom (0.8%), Italy (0.8%), Brazil (0.7%) and other (8.3%).
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
174.1 USD
Average target price
178.4 USD
Spread / Average Target
+2.49%
Consensus
1st Jan change Capi.
+12.33% 307 B $
+26.97% 666 B $
+19.17% 536 B $
+0.01% 377 B $
+15.07% 318 B $
-8.02% 207 B $
+4.05% 206 B $
-7.92% 191 B $
-4.27% 156 B $
-3.63% 117 B $
Other Pharmaceuticals
  1. Stock
  2. Equities
  3. Stock AbbVie Inc. - Nyse
+229% on MICROSOFT CORPORATION since our purchase on January 11, 2019
Replicate our performance
fermer